Pamvatamig
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Pamvatamig
- gamma1 heavy chain anti met homo sapiens 1 452 vh homo sapiens ighv7 4 1 02 95 9 ighd ighj5 02 100 cdr imgt 8 8 16 26 33 51 58 97 112 1 123 homo sapiens ighg1 03 g1m3 ng1m1ch1 r120 e12 m14 g1v72 ch3 d7 e24 ch1 r120 220 124 221 hinge 1 15 222 236 ch2 237 346 ch3 e12 362 m14 364 l7 d 357 l24 e 374 347 451 chs k2 del 452 124 452 226 214 disulfide with common kappa light chain homo sapiens 1 214 v kappa homo sapiens igkv1 39 01 100 igkj1 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 153 v101 191 108 214 gamma1 heavy chain anti egfr homo sapiens 1 451 vh homo sapiens ighv1 18 01 98 0 ighd ighj4 01 100 cdr imgt 8 8 15 26 33 51 58 97 111 1 122 homo sapiens ighg1 03 g1m3 ng1m1 ch1 r120 e12 m14 g1v73 ch3 k7 k22 ch1 r120 219 123 220 hinge 1 15 221 235 ch2 236 345 ch3 e12 361 m14 363 l7 k 356 t22 k 371 346 450 chs k2 del 451 124 452 226 214 disulfide with common kappa light chain homo sapiens 1 214 v kappa homo sapiens igkv1 39 01 100 igkj1 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 153 v101 191 108 214 dimer 232 231 235 234 bisdisulfide produced in a chinese hamster ovary cho
- Gamma1 heavy chain anti-MET Homo sapiens (1-452)[VH (Homo sapiens IGHV7-4-1*02 (95.9%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123)-Homo sapiens IGHG1*03, G1m3, nG1m1CH1 R120, E12, M14, G1v72 CH3 D7, E24 (CH1 R120(220) (124-221), hinge 1-15 (222-236), CH2 (237-346),CH3 E12 (362), M14 (364), L7>D (357), L24>E (374)(347-451), CHS K2>del (452)) (124-452)], (226-214')-disulfide with common kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01(100%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01(100%), Km3 A45.1 (153), V101 (191) (108'-214')],gamma1 heavy chain anti-EGFR Homo sapiens (1''-451'') [VH (Homo sapiens IGHV1-18*01 (98.0%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.15] (26''-33''.51''-58''.97''-111'')) (1''-122'')-Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, E12, M14,G1v73 CH3 K7, K22 (CH1 R120 (219'') (123''-220''),hinge 1-15 (221''-235''), CH2 (236''-345''), CH3 E12(361''), M14 (363''), L7>K (356''), T22>K (371'') (346''-450''), CHS K2>del (451'')) (124''-452'')], (226''-214''')-disulfide with common kappa light chain Homo sapiens (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-39*01(100%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'''-32'''.50'''-52'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'''), V101 (191''')(108'''-214''')], dimer (232-231'':235-234'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)
- Immunoglobulin G1 [357-aspartic acid,374-glutamic acid,de-C-terminal-lysine], anti-(human hepatocyte growth factor receptor c-Met) (human monoclonal MCLA-129 γ1-chain), disulfide with human monoclonal MCLA-129 κ-chain, (232→231′),(235→234′)-bis(disulfide) with immunoglobulin G1 [356-lysine,371-lysine,de-C-terminal-lysine] anti-(human epidermal growth factor receptor) (human monoclonal MCLA-129 γ1-chain) disulfide with human monoclonal MCLA-129 κ-chain
- immunoglobulin g1 357 aspartic acid 374 glutamic acid de c terminal lysine anti human hepatocyte growth factor receptor c met human monoclonal mcla 129 γ1 chain disulfide with human monoclonal mcla 129 κ chain 232 231 235 234 bis disulfide with immunoglobulin g1 356 lysine 371 lysine de c terminal lysine anti human epidermal growth factor receptor human monoclonal mcla 129 γ1 chain disulfide with human monoclonal mcla 129 κ chain
- immunoglobulin g1 kappa anti homo sapiens met met proto oncogene hepatocyte growth factor hgf receptor hgfr scatter factor sf receptor hgf sf receptor receptor tyrosine protein kinase c met papillary renal cell carcinoma 2 rccp2 and anti homo sapiens egfr epidermal growth factor receptor receptor tyrosine protein kinase erbb 1 erbb1 her1 her 1 erbb homo sapiens monoclonal antibody bispecific
- Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific
- mcla 129
- MCLA 129 [WHO-DD]
- mcla 129 who dd
- Mcla-129
- MCLA-129
- pamvatamig
- Pamvatamig
- pamvatamig [INN]
- PAMVATAMIG [USAN]
- pamvatamig inn
- pamvatamig usan
- CAS registry numbers
- 2750004-05-6
- ChEMBL ID
- CHEMBL5314862
- FDA ingredient codes (UNII)
- X3U67W8G5W
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mig
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0010150
- Highest recorded phase
- 1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 303 $ 302''
- Component
- Heavy chain: anti-MET (H)
- Type
- Protein
- Sequence
- QVQLVQSGSELKKPGASVKVSCKASGYTFTTYSMNWVRQAPGQGLEWMGWINTYTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARETYFYDRGGYPFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTDPPSREEMTKNQVSLTCEVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
- Component
- Heavy chain: anti-EGFR (H'')
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNANTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAKDRHWHWWLDAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTKPPSREEMTKNQVSLKCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 149''-205'' $ 150-206 $ 225''-214''' $ 226-214' $ 232-231'' $ 235-234'' $ 266''-326'' $ 267-327 $ 372''-430'' $ 373-431
Related records
Trials (5)
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
- Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
- Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
- Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
In development for (2)
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 2